immatics biotechnologies Extends and Closes Series D Round
July 17, 2014
immatics biotechnologies, a clinical-stage biopharma company developing immunotherapies that are active against cancer, has announced that it raised €22 million ($29.8 million) in Series D funding, bringing the round total to €34 million ($46 million). The company previously raised €12 million ($16.2 million) in the round in October 2013. The Series D funding was supported by existing investors including dievini Hopp Biotech, Wellington Partners and AT Impf, among others. immatics will use this funding to complete the current phase 3 trial with its lead cancer vaccine IMA901 in patients with renal cell carcinoma. The fundraising will also allow the company to invest in its XPRESIDENT platform to extend its Human Immunopeptidome Program, which is focused on identifying hundreds of novel, high quality targets for the most common cancer indications.